Federal and industry sponsors play distinct roles in US cancer trials

A comparative study published in JAMA Oncology reveals that federal and industry sponsors play distinct, interdependent roles within the United States cancer research ecosystem. Analyzing data from thousands of trials registered in the ClinicalTrials.gov database between 2008 and 2024, researchers identified clear functional differences between the two funding sources.

Industry-funded trials are more likely to focus on single-agent treatments and typically occupy the very early phase I or late-stage phase III positions in the clinical pipeline. In contrast, federally supported trials tend to focus on phase II studies, diagnostics, cancer prevention, screening, health services research, and supportive care.

Federal funding also plays a critical role in addressing the needs of pediatric and rare cancer patients, as well as studying multimodal treatment regimens or de-escalation strategies. The study suggests a model where federal sponsors provide the foundation through basic science discovery and early efficacy studies, while industry leads the late-stage trials necessary for regulatory approval.